Literature DB >> 16945413

Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.

Ridvan Ali, Fahir Ozkalemkas, Atilla Ozkan, Vildan Ozkocaman, Tulay Ozcelik, Ulku Ozan, Meral Kurt, Ahmet Tunali.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16945413     DOI： 10.1016/j.leukres.2006.07.017

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.

Authors:  Sachin S Saboo; Fiona Fennessy; Lina Benajiba; Jacob Laubach; Kenneth C Anderson; Paul G Richardson
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

3.  Large Plasmacytoma Occupying the Upper Limb in a Myeloma Patient.

Authors:  Junichiro Takano; Kensuke Ohikata; Daisuke Nagase; Toru Igari; Kazuhiko Natori; Shotaro Hagiwara
Journal:  Rare Tumors       Date:  2017-03-30

4.  A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment.

Authors:  Soo-Young Bae; Jae-Sook Ahn; Deok-Hwan Yang; Yeo-Kyeoung Kim; Jung-Joon Min; Ho-Chun Song; Hee-Seung Bom; Yong Yeon Jeong; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Case Rep Oncol       Date:  2011-02-25

5.  Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance.

Authors:  Hai-Fei Chen; Tian-Qin Wu; Zheng-Yang Li; Hong-Shi Shen; Jie-Qing Tang; Wei-Jun Fu; Zhen-Gang Yuan; Jian Hou
Journal:  Onco Targets Ther       Date:  2012-11-07       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.